Boehringer Ingelheim Venture Fund related stories
All articles and analysis
NBE-Therapeutics AG picks up about $20 mlnSwiss biotech company NBE-Therapeutics AG has raised about $20 million in Series B financing. PPF Group led the round with participation from other investors that included Boehringer Ingelheim Venture Fund.
- Promethera Biosciences pulls in $11 mln
Promethera Biosciences SA, a Belgian cell therapy and regenerative medicine company targeting liver diseases, has raised $11 million in funding. The investors included Vesalius Biocapital, SRIW, Boehringer Ingelheim Venture Fund, SMS Investments, Mitsubishi UFJ Capital Co. Ltd. and Cell Innovation Partners LP.
- Rigontec picks up Series A funds
Germany-based Rigontec, which focuses on RIG-I targeting RNA therapeutics, has raised 15 million euros in Series A funding. The investors included Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, Sunstone Capital and Wellington Partners Life Sciences.
- STAT Diagnostics raises $28.5 mln
STAT Diagnostics said April 10 that it closed a Series C financing round totaling 25 million Euros ($28.5 million) led by Gilde Healthcare. Existing investors Kurma Partners; Ysios Capital; Idinvest Partners; Boehringer Ingelheim Venture Fund; Caixa Capital Risc; and Axis also participated. Barcelona-based STAT Diagnostics is a medical diagnostics company.
- Israel's Metabomed raises $18 mln for cancer-metabolism drugs
Metabomed Ltd, an Israeli company developing drugs that target cancer metabolism, announced it has completed an extension of its Series A round from new and existing investors, bringing its total haul to $18 million. The new investors are Pfizer Inc and Arkin Holdings. They join existing investors MS Ventures, Boehringer Ingelheim Venture Fund, Pontifax Fund and the Technion Research and Development Foundation.
Sentien grabs Series A funds from BIVF and Canada's Portage BiotechMedford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund (BIVF) and Portage Biotech Inc, a Toronto-based developer of pharmaceutical and biotech products. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.
- Sentien grabs Series A funds from BIVF and Portage Biotech
Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund USA Inc and Portage Biotech Inc. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.
- ViraTherapeutics raises $4 mln
ViraTherapeutics GmbH said Wednesday it raised 3.6 million euros (US$4 million) in a first close of a Series A financing round. Boehringer Ingelheim Venture Fund and EMBL Ventures co-led the round, while Austria Wirtschaftsservice through its Venture-Capital-Initiative also invested. Innsbruck, Austria-based ViraTherapeutics is biopharmaceutical company developing cancer immunotherapies.
- Rigontec GmbH raises $5.3 mln in Series A
Rigontec GmbH said Tuesday it raised 4.8 million Euros (about US$5.3 mln) in a second closing of a series A round from Forbion Capital Partners and Sunstone Capital. Rigontec said total Series A funding was 14.25 million Euros (US$15.7 mln). Bonn, Germany-based Rigontech is a biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
- Promethera Biosciences nabs $31.4 Series C
Belgium-based Promethera Biosciences, a biotech firm that focuses on treating liver diseases, has closed its Series C round at $31.4 million. The investors included SFPI-FPIM, Vesalius Biocapital, Boehringer Ingelheim Venture Fund and SMS Investments.